Background: Lifileucel is a tumor-derived autologous T-cell therapy approved by the US FDA for the treatment of patients with advanced (unresectable or metastatic) melanoma previously treated with an immune checkpoint inhibitor and, if BRAF V600-mutated, a BRAF ± MEK inhibitor. The benefit of commercial lifileucel has not yet been investigated in a real-world clinical setting. We report the first multicenter experience of lifileucel in patients with advanced melanoma.
Building similarity graph...
Analyzing shared references across papers
Loading...
L. Karapetyan
J. Moser
B. Ting-Wen Ma
EJC Skin Cancer
Cornell University
Memorial Sloan Kettering Cancer Center
Moffitt Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Karapetyan et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69e9b71b85696592c86eb18f — DOI: https://doi.org/10.1016/j.ejcskn.2026.100897